Access count of this item: 95
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| ccr3.5384.pdf | 456.85 kB | Adobe PDF | View/Open |
| Title: | Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement |
| Authors: | Suga, Makiko Fukushima, Kentaro Ueda, Tomoaki Arai, Yasuyuki    https://orcid.org/0000-0002-9662-5093 (unconfirmed)Nakagawa, Shunsaku Minami, Yosuke Toda, Jun Hino, Akihisa Fujita, Jiro Yokota, Takafumi Hosen, Naoki |
| Author's alias: | 新井, 康之 中川, 俊作 |
| Keywords: | acute myeloid leukemia CNS involvement FLT3 inhibitor stem cell transplantation |
| Issue Date: | Feb-2022 |
| Publisher: | Wiley |
| Journal title: | Clinical Case Reports |
| Volume: | 10 |
| Issue: | 2 |
| Thesis number: | e05384 |
| Abstract: | FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation-positive acute myeloid leukemia (AML) has a poor prognosis. We report the first case of successful bridge therapy of novel FLT3 inhibitor, quizartinib, to umbilical cord blood stem cell transplantation for FLT3-ITD-positive AML-primary induction failure patients with central nervous system involvement. |
| Rights: | © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| URI: | http://hdl.handle.net/2433/293482 |
| DOI(Published Version): | 10.1002/ccr3.5384 |
| PubMed ID: | 35140970 |
| Appears in Collections: | Journal Articles |
This item is licensed under a Creative Commons License
